These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 15866683)

  • 1. Cyclosporine-based immunosuppressive strategies for kidney recipients: interim analysis of German data from the Multinational Observational Study (MOST).
    Kliem V; Fritsche L; Haller H; Suwelack B; Abendroth D; Fornara P; Pietruck F; Frei U; Donauer J; Lison AE; Michel U; Ulbricht B;
    Transplant Proc; 2005 Apr; 37(3):1597-600. PubMed ID: 15866683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
    Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine C2 levels in de novo renal allograft recipients: a German multicenter prospective observational study.
    Arns W; Zantvoort F; Abendroth D; Seiter H; Scheuermann EH; Albert U; Stahl R; Fornara P; Fricke L; Neumayer HH; Nagel E; Michel U; Ulbricht B
    Transplant Proc; 2005 Apr; 37(3):1612-5. PubMed ID: 15866687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to de novo immunosuppression and steroid elimination.
    Lebranchu Y
    Transplant Proc; 2009; 41(6 Suppl):S39-41. PubMed ID: 19651295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K
    Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
    Saudi J Kidney Dis Transpl; 2008 Jul; 19(4):564-70. PubMed ID: 18580014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
    Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
    Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G; Döhler B;
    Transplantation; 2009 Mar; 87(6):795-802. PubMed ID: 19300179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
    Grimbert P; Baron C; Fruchaud G; Hemery F; Desvaux D; Buisson C; Chopin D; Dahmane D; Remy P; Pastural M; Abbou C; Weil B; Lang P
    Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antilymphocyte globulin with a small dose of cyclosporine A and prednisone as the induction of immunosuppression in renal allograft recipients.
    Boratyńska M; Szepietowski T; Szewczyk Z; Szydłowski Z
    Arch Immunol Ther Exp (Warsz); 1992; 40(2):163-8. PubMed ID: 1299176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial.
    Hazzan M; Buob D; Labalette M; Provot F; Glowacki F; Hoffmann M; Copin MC; Noel C
    Transplantation; 2006 Sep; 82(5):657-62. PubMed ID: 16969289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bergamo Kidney Transplant Program.
    Perico N; Cravedi P; Ruggenenti P; Gotti E; Rota G; Locatelli G; Gambara V; Perna A; Rota S; Remuzzi G
    Clin Transpl; 2005; ():85-100. PubMed ID: 17424727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
    Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
    Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten years of cyclosporine use in renal transplantation: a single-center experience with 479 renal transplants.
    Lucan M; Iacob G; Lucan C; Lăpuşan C; Munteanu A; Sîrbu S
    Transplant Proc; 2004 Mar; 36(2 Suppl):177S-180S. PubMed ID: 15041332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
    Knight RJ; Kerman RH; Podder H; Katz SM; Van Buren CT; Kahan BD
    Transplant Proc; 2005 Mar; 37(2):1280-2. PubMed ID: 15848695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Schulz T; Papapostolou G; Schenker P; Kapischke M
    Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.